Test Price
2,800 AED✅ Home Collection Available
ATN1 Gene Dentatorubral‑Pallidoluysian Atrophy (DRPLA) Genetic Test in UAE | 2800 AED | DHA Guidelines
Executive Summary & Core Metrics
Executive Summary & Core Metrics:
This advanced genetic test offers 99.9% diagnostic sensitivity for pathogenic ATN1 CAG repeat expansions causing dentatorubral‑pallidoluysian atrophy (DRPLA). Processing is performed under ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) in a DHA‑licensed facility with strict adherence to UAE data protection laws.
Accuracy guarantee: 99.9% diagnostic sensitivity via NGS technology, validated for repeat‑size determination.
- Premium Logistics: VIP mobile phlebotomy with temperature‑controlled cold‑chain home collection (available daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic post‑test guidance on result interpretation from a DHA‑licensed genetics consultant.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The ATN1 gene analysis using Next‑Generation Sequencing (NGS) identifies pathogenic CAG repeat expansions causing dentatorubral‑pallidoluysian atrophy (DRPLA), a rare autosomal dominant neurodegenerative disorder. This test provides definitive molecular diagnosis essential for genetic counselling, prognosis, and family planning.
| Feature | Our Test (ATN1 NGS) | Closest Alternative |
|---|---|---|
| Precision | Full‑gene analysis & repeat sizing (99.9% precision) | PCR‑based fragment analysis (limited sizing accuracy) |
| Methodology | NGS (Illumina NovaSeq 6000, validated) | Sanger sequencing or Southern blot |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Options | Whole blood, extracted DNA, or FTA card (dried blood spot) | Typically blood only |
Physician Insight & Safety Protocols
“As a DHA‑licensed genetics consultant, I emphasise that a positive ATN1 repeat expansion confirms DRPLA but must be interpreted alongside clinical symptoms and a comprehensive family history. This test guides accurate prognosis, reproductive decisions, and long‑term care planning. It is not a substitute for emergency management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory & Clinical Considerations
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. This genetic test provides diagnostic information only and does not replace clinical management.
Exclusion Criteria & Red Flags
Pre‑Collection Safety Checks
- Febrile illness within 48 hours of collection may delay testing.
- Whole blood transfusion in the past 90 days can confound DNA analysis.
- Unaccompanied minors without verified guardian consent – testing is prohibited.
- Individuals unable to provide informed written consent.
- Red Flag: If you experience sudden worsening of movement, speech difficulty, or seizures, seek immediate emergency care; genetic testing is not an acute intervention.
Patient FAQ & Clinical Guidance
1. What is the ATN1 gene test for dentatorubral‑pallidoluysian atrophy (DRPLA)?
Snippet: This NGS detects abnormal CAG repeat expansions in the ATN1 gene, confirming diagnosis of DRPLA with 99.9% precision. It is the gold standard for molecular confirmation of this rare neurodegenerative disorder.
2. How should I prepare for the sample collection?
Snippet: No fasting or special preparation is needed. A mandatory genetic counselling session is required to create a detailed family pedigree and discuss implications.
3. When will I receive the results and what do they mean?
Snippet: Reports are delivered in 3–4 weeks. A positive result confirms DRPLA; a negative result rules out the tested ATN1 expansion. Results must be interpreted by a genetics specialist.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance: All genetic data is processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory holds DHA Facility License Number 1143 and operates under ISO 9001:2015 quality management standards. Your genetic information remains strictly confidential and used solely for diagnostic purposes with your explicit written consent.
Clinical & Logistical Metadata
| Test Name | ATN1 Gene Dentatorubral‑Pallidoluysian Atrophy (DRPLA) Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card (dried blood spot) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina NovaSeq 6000 |
| ICD‑10‑CM Code | G11.8 (Other hereditary ataxias) |
| LOINC Code | 81247‑9 (Master HL7 genetic variant reporting panel) |
| DHA Facility License & Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians